Brief: Chemomab Therapeutics Announces Positive Phase 2 Trial Results
25/07/2024 12:20
July 25 (Reuters) - Chemomab Therapeutics Ltd CMMB.O :
* CHEMOMAB THERAPEUTICS ANNOUNCES POSITIVE PHASE 2 TRIAL
RESULTS:
CM-101 ACHIEVES PRIMARY AND SECONDARY ENDPOINTS DEMONSTRATING
ANTI-FIBROTIC, ANTI-INFLAMMATORY AND ANTI-CHOLESTATIC EFFECTS IN
PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS
* CHEMOMAB THERAPEUTICS LTD - CM-101 DEMONSTRATES A
FAVORABLE
SAFETY PROFILE
* CHEMOMAB THERAPEUTICS LTD - CM-101 IMPROVES LIVER
STIFFNESS IN
PSC
Source text for Eikon: ID:nGNX3L4y6g
Further company coverage: CMMB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chemomab Therapeutics
See all newsBrief: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results And Provides Corporate Update
Chemomab Therapeutics Ltd expected to post a loss of 15 cents a share - Earnings Preview
Israel's Chemomab Q4 net loss narrows on lower R&D spend
Brief: Chemomab Therapeutics Announces Nebokitug Phase 2 Spring Trial Results
Brief: Chemomab Therapeutics Announces Third Quarter 2025 Financial Results And Provides Corporate Update